Innate and adaptive inflammation as a therapeutic target in vascular disease: The emerging role of statins

Journal of the American College of Cardiology

Volumn 63, Issue 23, 2014, Pages 2491-2502

  Tousoulis, Dimitris ^a   Psarros, Costas ^a   Demosthenous, Michael ^a   Patel, Rikhil ^b   Antoniades, Charalambos ^a,b   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

adhesion molecules; atherosclerosis; cardiovascular disease; cytokines; statins

Indexed keywords

ANTILIPEMIC AGENT; CELL ADHESION MOLECULE; CYTOKINE; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 18; ISOPRENOID; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; MEVINOLIN; NITRIC OXIDE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; VASCULAR CELL ADHESION MOLECULE 1; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; GAMMA INTERFERON; I KAPPA B ALPHA; I KAPPA B BETA; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; N(G),N(G) DIMETHYLARGININE; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; DNA DAMAGE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; OXIDATION REDUCTION STATE; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; VASCULAR DISEASE; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; MYOCARDITIS; CD4+ T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEART PROTECTION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNITY, INNATE; INFLAMMATION; MYOCARDITIS;

EID: 84899574075     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.01.054     Document Type: Review

References (92)

1. V.Z. Rocha, and P. Libby Obesity, inflammation, and atherosclerosis Nat Rev Cardiol 6 2009 399 409
2. T. Fukai Endothelial GTPCH in eNOS uncoupling and atherosclerosis Arterioscler Thromb Vasc Biol 27 2007 1493 1495
3. U.P. Steinbrecher, S. Parthasarathy, D.S. Leake, J.L. Witztum, and D. Steinberg Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids Proc Natl Acad Sci U S A 81 1984 3883 3887
4. J.A. Berliner, N. Leitinger, and S. Tsimikas The role of oxidized phospholipids in atherosclerosis J Lipid Res 50 Suppl 2009 S207 S212
5. Y.I. Miller, S.H. Choi, L. Fang, and S. Tsimikas Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis Subcell Biochem 51 2010 229 251
6. M. Naghavi, P. Libby, and E. Falk et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II Circulation 108 2003 1772 1778
7. A.R. Brasier The NF-kappaB regulatory network Cardiovasc Toxicol 6 2006 111 130
8. Y. Kabe, K. Ando, S. Hirao, M. Yoshida, and H. Handa Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus Antioxid Redox Signal 7 2005 395 403
9. T.D. Gilmore Introduction to NF-kappaB: players, pathways, perspectives Oncogene 25 2006 6680 6684
10. A. Tedgui, and Z. Mallat Cytokines in atherosclerosis: pathogenic and regulatory pathways Physiol Rev 86 2006 515 581
11. A.R. Brasier The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation Cardiovasc Res 86 2010 211 218
12. Z. Lu, Y. Li, J. Jin, X. Zhang, M.F. Lopes-Virella, and Y. Huang Toll-like receptor 4 activation in microvascular endothelial cells triggers a robust inflammatory response and cross talk with mononuclear cells via interleukin-6 Arterioscler Thromb Vasc Biol 32 2012 1696 1706
13. D. Tousoulis, C. Antoniades, and C. Stefanadis Assessing inflammatory status in cardiovascular disease Heart 93 2007 1001 1007
14. E. Shaulian, and M. Karin AP-1 as a regulator of cell life and death Nat Cell Biol 4 2002 E131 E136
15. H.B. Schonthaler, J. Guinea-Viniegra, and E.F. Wagner Targeting inflammation by modulating the Jun/AP-1 pathway Ann Rheum Dis 70 Suppl 1 2011 i109 i112
16. A.C. Newby Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture Physiol Rev 85 2005 1 31
17. Y.R. Chen, A. Shrivastava, and T.H. Tan Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate Oncogene 20 2001 367 374
18. H. Ait-Oufella, S. Taleb, Z. Mallat, and A. Tedgui Recent advances on the role of cytokines in atherosclerosis Arterioscler Thromb Vasc Biol 31 2011 969 979
19. R.L.K. Virchow Cellular Pathology as Based Upon Physiological and Pathological Histology 1863 JB Lippincott Philadelphia, PA
20. I. Kriszbacher, M. Koppan, and J. Bodis Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 353 2005 429 430 author reply 429-30
21. T.H. Mogensen Pathogen recognition and inflammatory signaling in innate immune defenses Clin Microbiol Rev 22 2009 240 273
22. A. Niessner, and C.M. Weyand Dendritic cells in atherosclerotic disease Clin Immunol 134 2010 25 32
23. Z. Mallat, S. Taleb, H. Ait-Oufella, and A. Tedgui The role of adaptive T cell immunity in atherosclerosis J Lipid Res 50 Suppl 2009 S364 S369
24. C. Antoniades, C. Bakogiannis, D. Tousoulis, A.S. Antonopoulos, and C. Stefanadis The CD40/CD40 ligand system: linking inflammation with atherothrombosis J Am Coll Cardiol 54 2009 669 677
25. E. Lutgens, D. Lievens, L. Beckers, M. Donners, and M. Daemen CD40 and its ligand in atherosclerosis Trends Cardiovasc Med 17 2007 118 123
26. J.F. Kearney Immune recognition of OxLDL in atherosclerosis J Clin Invest 105 2000 1683 1685
27. J. Shalhoub, M.A. Falck-Hansen, A.H. Davies, and C. Monaco Innate immunity and monocyte-macrophage activation in atherosclerosis J Inflamm (Lond) 8 2011 9
28. S. Wolfrum, K.S. Jensen, and J.K. Liao Endothelium-dependent effects of statins Arterioscler Thromb Vasc Biol 23 2003 729 736
29. D. Tousoulis, C. Antoniades, and C. Vasiliadou et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus Heart 93 2007 244 246
30. C. Napoli, V. Sica, and F. de Nigris et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension Am Heart J 148 2004 e5
31. M. Wang, J. Zhang, and G. Spinetti et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats Am J Pathol 167 2005 1429 1442
32. W.L. Shen, P.J. Gao, and Z.Q. Che et al. NAD(P)H oxidase-derived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotypic differentiation Biochem Biophys Res Commun 339 2006 337 343
33. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
34. C. Antoniades, C. Bakogiannis, and P. Leeson et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling Circulation 124 2011 335 345
35. C. Antoniades, C. Bakogiannis, and D. Tousoulis et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity Circulation 122 Suppl 2010 S66 S73
36. M.K. Jain, and P.M. Ridker Anti-inflammatory effects of statins: clinical evidence and basic mechanisms Nat Rev 4 2005 977 987
37. U. Schonbeck, and P. Libby Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109 2004 II18 II26
38. U. Rauch, J.I. Osende, and J.H. Chesebro et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins Atherosclerosis 153 2000 181 189
39. P.M. Ridker, E. Danielson, and F.A. Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
40. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
41. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
42. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
43. J.C. LaRosa, S.M. Grundy, and D.D. Waters et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
44. J.R. Downs, M. Clearfield, and S. Weis et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
45. J. Shepherd, S.M. Cobbe, I. Ford West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
46. M.A. Albert, E. Danielson, N. Rifai, and P.M. Ridker Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
47. E. Ascer, M.C. Bertolami, and M.L. Venturinelli et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients Atherosclerosis 177 2004 161 166
48. C. Bulcao, F.F. Ribeiro-Filho, A. Sanudo, and S.G. Roberta Ferreira Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome Am J Cardiovasc Drugs 7 2007 219 224
49. M.A. van de Ree, M.V. Huisman, H.M. Princen, A.E. Meinders, and C. Kluft Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus Atherosclerosis 166 2003 129 135
50. S. Wassmann, K. Wassmann, and G. Nickenig Modulation of oxidant and antioxidant enzyme expression and function in vascular cells Hypertension 44 2004 381 386
51. K. Umeji, S. Umemoto, and S. Itoh et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia Am J Physiol 291 2006 H2522 H2532
52. J. Haendeler, J. Hoffmann, A.M. Zeiher, and S. Dimmeler Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins Circulation 110 2004 856 861
53. F. Degraeve, M. Bolla, and S. Blaie et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins J Biol Chem 276 2001 46849 46855
54. H. Matsuno, M. Takei, H. Hayashi, K. Nakajima, A. Ishisaki, and O. Kozawa Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries J Cardiovasc Pharmacol 43 2004 333 340
55. W. Dichtl, J. Dulak, and M. Frick et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells Arterioscler Thromb Vasc Biol 23 2003 58 63
56. M. Jiang, H. Bujo, and Y. Zhu et al. Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells Biochem Biophys Res Commun 348 2006 1367 1377
57. N. Ohnesorge, D. Viemann, and N. Schmidt et al. Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4) J Biol Chem 285 2010 26199 26210
58. M. Jougasaki, T. Ichiki, Y. Takenoshita, and M. Setoguchi Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells Br J Pharmacol 159 2010 1294 1303
59. S. Kagami, T. Owada, and H. Kanari et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells Int Immunol 21 2009 679 689
60. Y.C. Kim, K.K. Kim, and E.M. Shevach Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction Immunology 130 2010 484 493
61. D.X. Bu, M. Tarrio, and N. Grabie et al. Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses J Clin Invest 120 2010 1961 1970
62. L.V. Sinclair, D. Finlay, and C. Feijoo et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking Nat Immunol 9 2008 513 521
63. R.J. Wagner, K.A. Martin, R.J. Powell, and E.M. Rzucidlo Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR Am J Physiol Cell Physiol 299 2010 C119 C127
64. K. Sato, T. Nuki, K. Gomita, C.M. Weyand, and N. Hagiwara Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome Atherosclerosis 213 2010 33 39
65. M. Kimura, I. Kurose, J. Russell, and D.N. Granger Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats Arterioscler Thromb Vasc Biol 17 1997 1521 1526
66. A. Rezaie-Majd, T. Maca, and R.A. Bucek et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients Arterioscler Thromb Vasc Biol 22 2002 1194 1199
67. I. Martin-Padura, S. Lostaglio, and M. Schneemann et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration J Cell Biol 142 1998 117 127
68. S. Wang, J.P. Dangerfield, R.E. Young, and S. Nourshargh PECAM-1, alpha6 integrins and neutrophil elastase cooperate in mediating neutrophil transmigration J Cell Sci 118 2005 2067 2076
69. W.H. Su, H.I. Chen, and C.J. Jen Differential movements of VE-cadherin and PECAM-1 during transmigration of polymorphonuclear leukocytes through human umbilical vein endothelium Blood 100 2002 3597 3603
70. K. Wennerberg, and C.J. Der Rho-family GTPases: it's not only Rac and Rho (and I like it) J Cell Sci 117 2004 1301 1312
71. K. Kaibuchi, S. Kuroda, and M. Amano Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells Annu Rev Biochem 68 1999 459 486
72. C.V. Carman, C.D. Jun, A. Salas, and T.A. Springer Endothelial cells proactively form microvilli-like membrane projections upon intercellular adhesion molecule 1 engagement of leukocyte LFA-1 J Immunol 171 2003 6135 6144
73. B. Wojciak-Stothard, L. Williams, and A.J. Ridley Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering J Cell Biol 145 1999 1293 1307
74. S.A. Holstein, C.L. Wohlford-Lenane, and R.J. Hohl Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB J Biol Chem 277 2002 10678 10682
75. K. Stamatakis, E. Cernuda-Morollon, O. Hernandez-Perera, and D. Perez-Sala Isoprenylation of RhoB is necessary for its degradation. A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway J Biol Chem 277 2002 49389 49396
76. H. Wei, L. Fang, J. Song, and S. Chatterjee Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells FEBS Lett 579 2005 1272 1278
77. E.S. Xenos, S.L. Stevens, M.B. Freeman, D.C. Cassada, and M.H. Goldman Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 expression on human endothelial cells Ann Vasc Surg 19 2005 386 392
78. S.L. Molyneux, J.M. Young, C.M. Florkowski, M. Lever, and P.M. George Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev 29 2008 71 82
79. G.P. Littarru, and L. Tiano Bioenergetic and antioxidant properties of coenzyme Q10: recent developments Mol Biotechnol 37 2007 31 37
80. R. Deichmann, C. Lavie, and S. Andrews Coenzyme Q10 and statin-induced mitochondrial dysfunction Ochsner J 10 2010 16 21
81. G.P. Littarru, and P. Langsjoen Coenzyme Q10 and statins: biochemical and clinical implications Mitochondrion 7 Suppl 2007 S168 S174
82. T. Rundek, A. Naini, R. Sacco, K. Coates, and S. DiMauro Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke Arch Neurol 61 2004 889 892
83. R. Laaksonen, K. Jokelainen, and J. Laakso et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle Am J Cardiol 77 1996 851 854
84. J.J. McMurray, P. Dunselman, and H. Wedel et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) J Am Coll Cardiol 56 2010 1196 1204
85. P. Amarenco, L.B. Goldstein, and M. Szarek et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial Stroke 38 2007 3198 3204
86. F.M. Sacks, M.A. Pfeffer, L.A. Moye Cholesterol and Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
87. P.W. Serruys, P. de Feyter, and C. Macaya et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
88. P.S. Sever, B. Dahlof, and N.R. Poulter et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
89. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
90. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
91. C.P. Cannon, E. Braunwald, and C.H. McCabe et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
92. J. Kjekshus, E. Apetrei, and V. Barrios et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261